As announced on September 2, 2021, Hillrom has entered into a definitive merger agreement under which Baxter has agreed to acquire Hillrom for $156.00 per share in cash. The transaction is subject to the approval of Hillrom shareholders and the satisfaction of customary closing conditions, including regulatory approvals. Hillrom continues to expect the transaction to close by early 2022. As a result of the proposed transaction, the company is not providing financial guidance for fiscal 2022.